• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    4/14/22 1:35:34 PM ET
    $BFRI
    $CLRB
    $HSTO
    $ISO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRI alert in real time by email

    Gainers

    • Kaleido Biosciences (NASDAQ:KLDO) stock increased by 24.9% to $0.38 during Thursday's regular session. As of 13:30 EST, Kaleido Biosciences's stock is trading at a volume of 53.0 million, which is 1374.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.0 million.
    • Verastem (NASDAQ:VSTM) stock moved upwards by 21.89% to $1.86. As of 13:30 EST, Verastem's stock is trading at a volume of 24.4 million, which is 1316.4% of its average full-day volume over the last 100 days. The company's market cap stands at $347.5 million.
    • Trevi Therapeutics (NASDAQ:TRVI) shares rose 19.06% to $3.31. The current volume of 2.2 million shares is 203.7% of Trevi Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $117.1 million.
    • Lexaria Bioscience (NASDAQ:LEXX) shares rose 15.85% to $3.8. As of 13:30 EST, this security is trading at a volume of 47.4 million shares, making up 82796.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.6 million. As per the press release, Q2 earnings came out 3 days ago.
    • Cellectar Biosciences (NASDAQ:CLRB) shares rose 15.37% to $0.69. Trading volume for Cellectar Biosciences's stock is 215.8K as of 13:30 EST. This is 110.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $42.4 million.
    • Lyra Therapeutics (NASDAQ:LYRA) shares rose 14.66% to $7.16. As of 13:30 EST, Lyra Therapeutics's stock is trading at a volume of 262.0K, which is 144.2% of its average full-day volume over the last 100 days. The company's market cap stands at $93.0 million.

    Losers

    • Histogen (NASDAQ:HSTO) shares fell 32.4% to $0.26 during Thursday's regular session. The current volume of 13.6 million shares is 539.4% of Histogen's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $13.1 million.
    • Protagonist Therapeutics (NASDAQ:PTGX) shares fell 20.97% to $20.17. Trading volume for this security as of 13:30 EST is 3.6 million, which is 495.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $976.5 million.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) stock decreased by 18.88% to $1.59. Lixte Biotech Hldgs's stock is trading at a volume of 1.7 million shares as of 13:30 EST. This is 55.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.8 million.
    • Biofrontera (NASDAQ:BFRI) shares declined by 17.34% to $4.1. The current volume of 2.7 million shares is 96.5% of Biofrontera's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $70.1 million. The company's, Q4 earnings came out 4 days ago.
    • Pyxis Oncology (NASDAQ:PYXS) stock declined by 14.84% to $3.86. The company's market cap stands at $126.7 million.
    • IsoPlexis (NASDAQ:ISO) stock declined by 14.71% to $2.32. As of 13:30 EST, IsoPlexis's stock is trading at a volume of 91.8K, which is 116.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $90.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BFRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRI
    $CLRB
    $HSTO
    $ISO

    CompanyDatePrice TargetRatingAnalyst
    Cellectar Biosciences Inc.
    $CLRB
    3/10/2026$10.00Hold → Buy
    Maxim Group
    Verastem Inc.
    $VSTM
    2/4/2026$18.00Buy
    H.C. Wainwright
    Trevi Therapeutics Inc.
    $TRVI
    11/13/2025$13.00Outperform
    Leerink Partners
    Pyxis Oncology Inc.
    $PYXS
    11/3/2025$9.00Buy
    Stifel
    Verastem Inc.
    $VSTM
    10/16/2025Overweight
    Cantor Fitzgerald
    Protagonist Therapeutics Inc.
    $PTGX
    9/17/2025$72.00Overweight
    Barclays
    Protagonist Therapeutics Inc.
    $PTGX
    9/12/2025$73.00Outperform
    Leerink Partners
    Pyxis Oncology Inc.
    $PYXS
    9/4/2025$5.00Buy
    Guggenheim
    More analyst ratings

    $BFRI
    $CLRB
    $HSTO
    $ISO
    SEC Filings

    View All

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    3/10/26 4:00:37 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)

    3/9/26 4:35:04 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Biofrontera Inc. (0001858685) (Filer)

    3/9/26 9:20:28 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    $CLRB
    $HSTO
    $ISO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 7, 2021 - Coronavirus (COVID-19) Update: September 7, 2021

    For Immediate Release: September 07, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Kaleido Biosciences, Inc. for not complying with federal laws and regulations, including laws and regulations to protect individuals participatin

    9/7/21 4:11:11 PM ET
    $KLDO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BFRI
    $CLRB
    $HSTO
    $ISO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Weber Kevin Daniel

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:33:07 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Luebbert Hermann converted options into 137,500 shares, increasing direct ownership by 90% to 290,211 units (SEC Form 4)

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:31:43 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Leffler Eugene Frederick converted options into 87,500 shares, increasing direct ownership by 100% to 175,000 units (SEC Form 4)

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:30:26 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    $CLRB
    $HSTO
    $ISO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bunka Christopher bought $25,241 worth of shares (27,500 units at $0.92) (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 5:12:54 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mckechnie William Edward bought $4,532 worth of shares (5,000 units at $0.91), increasing direct ownership by 38% to 18,191 units (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 12:37:08 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CSO Docherty John Martin bought $4,989 worth of shares (5,376 units at $0.93) (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 11:34:10 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    $CLRB
    $HSTO
    $ISO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

    NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m. ET, to provide business updates and review the Company's financial results for the fourth quarter and year ended December 31, 2025.  Conference Call and WebcastTo register for the live co

    3/10/26 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

    • Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical development • Acne vulgaris represents a promising potential future indication for Ameluz®, significantly broadening the Company's dermatology pipeline WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced results of its Phase 2b clinical trial evaluating Ameluz® (aminolevulinic acid HCL) topical gel, 1

    3/9/26 9:15:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    $CLRB
    $HSTO
    $ISO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cellectar Biosciences upgraded by Maxim Group with a new price target

    Maxim Group upgraded Cellectar Biosciences from Hold to Buy and set a new price target of $10.00

    3/10/26 8:36:07 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Verastem with a new price target

    H.C. Wainwright initiated coverage of Verastem with a rating of Buy and set a new price target of $18.00

    2/4/26 8:31:21 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Trevi Therapeutics with a new price target

    Leerink Partners initiated coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $13.00

    11/13/25 9:10:57 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    $CLRB
    $HSTO
    $ISO
    Leadership Updates

    Live Leadership Updates

    View All

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With

    2/3/26 6:45:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

    John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will jo

    12/15/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    $CLRB
    $HSTO
    $ISO
    Financials

    Live finance-specific insights

    View All

    Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

    NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m. ET, to provide business updates and review the Company's financial results for the fourth quarter and year ended December 31, 2025.  Conference Call and WebcastTo register for the live co

    3/10/26 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

    On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the year ended December 31

    3/4/26 7:15:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    $CLRB
    $HSTO
    $ISO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

    SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/14/24 7:48:39 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 6:25:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care